ESTRO 38 Abstract book

S848 ESTRO 38

survival and distance-free relapse-free survival were 52,95%, 78,26%, 76,10% respectively, counting on a overall survival of 98,04%. We used CTCAE 4.0 scale to measure toxicity. 46 patients (90.20%) had no acute gastrointestinal toxicity, 4 (7.84%) had acute grade 1 gastrointestinal toxicity. In case of acute genitourinary toxicity, 41 patients (80.39%) did not experience any toxicity while 8 (15.69%) had grade 1 toxicity. Only one patient suffered late toxicity, a pathological fracture, one year after administration of SBRT.

Purpose or Objective To analyze the survival and toxicity in patients with oligometastatic prostate cancer treated in our center with stereotactic body radiation therapy (SBRT). Material and Methods We retrospectively reviewed 51 patients with oligometastatic prostate cancer that received SBRT to treat malignant adenopathies and bone metastasis between March 2014 and August 2018. We analyzed metastasis control (MC), disease-free survival (DFS), biochemical progression-free survival (BPFS), distant progression-free survival (DPFS), and overall survival (OS).

Patient and disease characteristics (n=51) Characteristics

Value (%) 68,59

Age at diagnosis in years (median)

9 (17,65) 22 (43,14) 11 (21,57) 8 (15,69) 1 (1,96) 47 (68,12) 22 (31,88) 35 (68,63) 8 (15,69) 3 (5,88) 5 (9,80) 13 (25,49) 11 (21,57) 22 (43,14) 3 (5,88) 2 (3,92) 4 (7,84) 47 (92,16) 0 (0) 46 (90,20) 1 (1,96) 3 (5,88) 1 (1,96) 20 (39,22) 1 (1,96) 19 (37,25) 7 (13,73) 3 (5,88) 1 (1,96) 37 (72,55) 14 (27,45)

Gleason

6 7 8 9

10

Regions

treated

(69) node

Lymph

Bone

PSA

pre-treatment

(ng/ml) 0-5

>5-10 >10-20 >20

TNM

T1 T2 T3 T4

Unkonwn

Nx N1

N2

M0 M1a M1b

Unknown

Conclusion Stereotactic body radiation therapy used in oligometastatic prostate cancer patients provided optimal control of metastasis and acceptable toxicity. It is a good therapy for bone and lymph nodes lesions. EP-1571 Pelvis Hypofractionarion in IMRT+IGRT:15 fractions and prostate HDR Brachytherapy. Toxicity analysis P. Castro Peña 1 , E. Marinello 1 , P. Murina 1 , Y. Schworer 1 , L. Suarez Villasmil 1 , D. Venencia 1 , S. Zunino 1 1 Instituto Zunino - Fundacion Marie Curie, Radiation Oncology, Cordoba, Argentina Purpose or Objective To analyze urinary and rectal toxicity in patients with prostate cancer undergoing combination treatment with High Rate Dose Prostate Brachytherapy (HDR-B) plus External Beam Radiation Therapy IMRT + IGRT in 15 fractions, with pelvic lymph nodes irradiation. Material and Methods Between June '15 and August'18, 38 patients with positive prostate cancer biopsy were treated. The average initial PSA was 22.34 ng/ml [4.19-84]. The average prostate volume was 40.5 g [15-75]. The distribution of patients by risk groups was: Low risk 0% (0), Intermediate risk 10.5% (4), High risk 73.7% (28), Locally advanced 13% and and Metastatic 2% . 100% of the patients received neoadjuvant, concomitant and adjuvant hormonal treatment. All the patients were

Primary

treatment RP RP+LP RT RP+RT BT

HT

Hormonal

treatment Yes

No

Abbreviantions: PSA = prostate-specific antigen; RP = radical prostatectomy; RT = radiation therapy; LP=lymphadenectomy; BT = Brachytherapy; HT = Hormonal treatment.

Results We included 51 patients with 69 lesions, of which 100% were hormone-sensitive. 72% were being treated with hormone therapy (analogue LHRH). 11.76% became castrate resistant during follow-up. The number of lesions treated was 22 bone metastasis and 47 malignant lymphadenopathies. The treatment was administered with intensity-modulated radiotherapy guided by daily image by cone-beam and simmetry device for respiratory control. The patients were immobilized by Body Fix system and the treatment dose used was 45Gy in 6 fractions of 7.5Gy, twice a week for lymph nodes and 16Gy single session for bone lesions. Estimated Metastasis control at 2 years was 86.27%. Disease-free survival, biochemical progression-free